Compositions and methods for treating autism
The invention provides compositions and methods of treating autism. Specifically, the invention relates to treating the core symptoms of autism by administering α-methyl-DL-tyrosine.
1. A method for treating an autism in a subject in need thereof, the method comprising administering to said subject a composition comprising a therapeutically effective amount of α-methyl-DL-tyrosine, and a pharmaceutically acceptable carrier.
2. The method of claim 1 , wherein the composition comprises α-methyl-DL-tyrosine in an amount ranging from about 50 mg (w/w) to about 1000 mg (w/w).
3. The method of claim 1 , wherein the composition comprises α-methyl-DL-tyrosine in an amount of about 100 mg (w/w/).
4. The method of claim 1 , wherein the composition comprises α-methyl-DL-tyrosine in an amount of about 200 mg (w/w/).
5. The method of claim 1 , wherein the composition comprises α-methyl-DL-tyrosine in an amount of about 250 mg (w/w/).
6. The method of claim 1 , wherein the composition comprises α-methyl-DL-tyrosine in an amount of about 300 mg (w/w/).
7. The method of claim 1 , wherein the composition is administered in a plurality of divided doses.
8. The method of claim 1 , wherein the composition is administered in a plurality of divided doses.
9. The method of claim 1 , wherein the composition is administered as a single sustained release daily dose.
10. The method of claim 1 , wherein the composition is administered as a chewable dosage form for pediatric patients.
11. The method of claim 1 , wherein the composition is administered two times per day.
12. The method of claim 1 , wherein the composition is administered three times per day.
13. The method of claim 1 , further comprising administering to said subject a therapeutically effective amount of a central nervous system (CNS) agent.
14. The method of claim 13 , wherein said agent is Y-aminobutyric acid (GABA).
15. The method of claim 13 , wherein said agent is beta-adrenergic agonist.
16. The method of claim 1 , wherein the composition is administered orally.
17. The method of claim 16 , wherein the composition is in a form of a capsule or a tablet.
18. The method of claim 1 , wherein said subject is a human patient between 3 years of age and 21 years of age.
19. The method of claim 1 , wherein said subject is an adult human patient.